$The tamoxifen paradox—influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer$
QR Code

The tamoxifen paradox—influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer

Summary Our data demonstrate that tamoxifen does not reduce fracture risk. Close surveillance is necessary to prevent bone loss in premenopausal women with breast cancer upon treatment initiation. Introduction Endocrine treatment of breast cancer may interfere with bone turnover and influence fractu...

Full description

Saved in:

Bibliographic Details
Published in:	Osteoporosis international Vol. 29; no. 11; pp. 2557 - 2564
Main Authors:	Kyvernitakis, I., Kostev, K., Hadji, P.
Format:	Journal Article
Language:	English
Published:	London Springer London 01-11-2018 Springer Nature B.V
Subjects:	Adjuvants Adolescent Adult Age Factors Aged Aged, 80 and over Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Bone cancer Bone loss Bone turnover Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Chemotherapy, Adjuvant - adverse effects Databases, Factual Endocrinology Female Fractures Germany - epidemiology Health risk assessment Humans Incidence Medicine Medicine & Public Health Middle Aged Original Article Orthopedics Osteoporosis Osteoporotic Fractures - chemically induced Osteoporotic Fractures - epidemiology Patients Post-menopause Postmenopause Premenopause Retrospective Studies Rheumatology Risk Assessment - methods Tamoxifen Tamoxifen - adverse effects Tamoxifen - therapeutic use Young Adult Germany Osteoporosis Breast cancer Fracture risk Tamoxifen Menopause
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!